Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

BACKGROUND: Direct thrombin inhibitors may lead to falsely low fibrinogen results. The interference of bivalirudin on fibrinogen assays has not been thoroughly evaluated. This study investigates the interference of bivalirudin on fibrinogen detection and the potential use of activated carbon to address this issue. METHODS: Normal pooled plasma from 20 healthy subjects was spiked with increasing bivalirudin concentrations (0-6.4 μg/mL). Interference of bivalirudin on fibrinogen testing was evaluated by comparing three Clauss-method assays (HemosIL Fibrinogen-C XL; STA-Fibrinogen; Dade Thrombin) to an immunoassay (N Antiserum to Human Fibrinogen reagent, NAHF). Activated partial thromboplastin time (APTT) and fibrinogen results were analyzed before and after the addition of activated carbon (AC) to evaluate the absorption of bivalirudin by AC. RESULTS: The NAHF immunoassay remained unaffected by bivalirudin (p = 0.27). All three Clauss-methods assays showed a significant downward trend with the increase of bivalirudin concentration (STA-Fibrinogen: p = 0.012, Dade Thrombin: p < 0.001, Fibrinogen-C XL: p < 0.001). When compared to their respective baselines, STA-Fibrinogen exhibited a reduction of 16%, Dade Thrombin showed a reduction of 40%, and Fibrinogen-C XL displayed a decrease of up to 89%. Neither STA-Fibrinogen nor Dade Thrombin displayed a significant downward trend when the APTT ratio did not exceed 2.5. After the addition of AC, SynthASil APTT and HemosIL Fibrinogen-C XL levels of all samples containing varying concentrations of bivalirudin returned to near baseline. CONCLUSION: The influences of bivalirudin on fibrinogen assays vary significantly. Activated carbon can effectively remove bivalirudin from plasma, thereby eliminating its interference on fibrinogen testing.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Laboratory methods paper resolving the pre-analytical interference of bivalirudin (a leech-derived direct thrombin inhibitor) with fibrinogen assays using activated-carbon pretreatment, allowing accurate hemostasis monitoring on therapy.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

More peer-reviewed studies in Arzneimittelentwicklung.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Investigation of oxidant-antioxidant status in patients treated with hirudotherapy: an experimental study — Sarikan I, Savas H (2024)
• Leech therapeutic applications — Abdualkader A et al. (2013)
• Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report — Akalın Ç, Ekmen N (2020)
• Leech therapy: a history — Hyson J (2005)

Browse all ASH-analysed research →